Group 1: Company Performance - In the first half of 2024, the company achieved operating revenue of 144 million CNY, an increase of 18.44% compared to the same period last year [6] - The net profit attributable to shareholders was 24.14 million CNY, a decrease of 36.29% year-on-year [6] - The total assets reached 2.271 billion CNY, reflecting a slight decrease of 1.37% due to dividend distribution [6] Group 2: Business Growth and Client Pipeline - As of June 30, 2024, the company had 216 confirmed drug development pipelines using its cell culture products, an increase of 46 pipelines (27.06%) compared to the end of 2023 [4] - The company has served over 1,400 domestic and international biopharmaceutical enterprises and research institutions [7] - The CDMO business assisted clients in obtaining 5 clinical approvals and one project received NMPA market approval [4] Group 3: Product Development and Innovation - The company developed 15 customized CHO cell culture products, with over half used in pilot scale projects [5] - The company’s CDMO platform has completed construction and entered trial production, enhancing service capabilities [5] - The company’s R&D investment totaled approximately 15.38 million CNY, accounting for 10.71% of operating revenue, although it decreased by 25.71% year-on-year [6] Group 4: Financial Metrics and Challenges - The company reported a gross profit margin decline due to structural impacts from its two main business segments [9] - Operating costs increased primarily due to rising revenue and expenses related to the CDMO platform [6] - The overseas revenue reached 45.20 million CNY, a significant increase of 226.58% compared to the previous year [6] Group 5: Strategic Adjustments and Future Outlook - The company plans to increase mid-term cash dividends to 2.20 CNY per 10 shares, reflecting a commitment to investor returns [7] - Adjustments to the stock incentive plan were made to align performance targets with current market conditions and company strategy [8] - The company aims to enhance operational efficiency and strengthen internal management to prepare for future growth [7]

| 回购方案首次披露日 | 2023/10/31，由公司董事长、总经理肖志华先生提议 | | --- | --- | | 回购方案实施期限 | 2023/10/28~2024/10/27 | | 预计回购金额 | 元 50,000,000 元~100,000,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,223,706 股 | | 累计已回购股数占总股本 | 1.0662% | | 比例 | | | 累计已回购金额 | 50,998,163.75 元 | | 实际回购价格区间 | 25.79 元/股~58.00 元/股 | 证券代码：688293 证券简称：奥浦迈 公告编号：2024-056 上海奥浦迈生物科技股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股 本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 注：因公司 2023 年度实施差异化 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2024-057 上海奥浦迈生物科技股份有限公司 关于调整公司 2024 年中期利润分配方案每股分配比 例的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 3、如在2024年中期利润分配预案相关公告披露之日起至实施权益分派股权 登记日期间，公司总股本发生变动的，公司拟维持利润分配总额不变，相应调整 每股利润分配比例。具体内容详见公司于2024年8月27日刊载于上海证券交易所 网站（www.sse.com.cn）的《关于公司2024年中期利润分配预案的公告》。 二、调整后利润分配方案 重要内容提示： 每股分红金额：每股派发现金红利由0.22元（含税）调整为每股派发现金 红利0.22032元（含税）。 本次调整原因：自2024年中期利润分配预案相关公告披露之日起至本公 告披露日，上海奥浦迈生物科技股份有限公司（以下简称"公司"或"奥浦迈"） 通过上海证券交易所交易系统以集中竞价交易方式实施股份回购，故本次实际参 与利润分配的股份数量发生变动。公司按照分配总额不变的原则， ...

大股东及董监高持股的基本情况 本次减持计划实施前，宁波梅山保税港区铧杰股权投资管理有限公司－华杰 （天津）医疗投资合伙企业（有限合伙）（以下简称"华杰投资"）持有上海奥浦 迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）股份 10,154,542 股， 持股比例 8.85%。前述股份来源于公司首次公开发行前持有的股份数量，已于 2023 年 9 月 4 日解除限售并上市流通。 减持计划的实施结果情况 2024 年 5 月 7 日，公司于上海证券交易所网站（www.sse.com.cn）披露了《关 于持股 5%以上股东通过大宗交易减持股份计划公告》，因股东自身资金需求， 华杰投资计划自 2024 年 5 月 28 日至 2024 年 8 月 27 日期间通过大宗交易的方式 减持公司股份不超过 2,180,676 股，占公司总股本的比例不超过 1.9%。2024 年 8 月 28 日，公司收到公司持股 5%以上股东华杰投资发来的《关于股份减持结果告 1 知函》，在本次减持计划期间，华杰投资通过大宗交易的方式累计减持公司股份 225,000 股，累计减持占公司总股本的比例为 0.20%，本次减持计划时间已届满 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2024-046 上海奥浦迈生物科技股份有限公司 关于公司 2024 年半年度募集资金实际存放与使用情 况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》和《上 海证券交易所科创板股票上市规则》等相关法律法规的规定，上海奥浦迈生物科 技股份有限公司（以下简称"奥浦迈"或"公司"）董事会编制了2024年半年度 募集资金实际存放与使用情况专项报告，现将相关情况公告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据中国证券监督管理委员会于2022年6月13日出具的《关于同意上海奥浦 迈生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕1232 号），并经上海证券交易所同意，公司首次公开发行人民币普通股2,049.5082万 股，每股面值为人民币1元，发行价格为每股人民币80.20元，募集资金总 ...

优化，成就与众不同 Optimization Makes Differences 上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划实施考核管理办法 （修订稿） 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"奥浦迈"）为进一步完善公司法 人治理结构，建立、健全公司长效激励约束机制，吸引和留住公司核心管理、技术和业务人 才，充分调动其积极性和创造性，有效提升核心团队凝聚力和企业核心竞争力，有效地将股 东、公司和核心团队三方利益结合在一起，使各方共同关注公司的长远发展，确保公司发展 战略和经营目标的实现，在充分保障股东利益的前提下，制定了《上海奥浦迈生物科技股份 有限公司 2023 年限制性股票激励计划》。 为保证公司 2023 年限制性股票激励计划（以下简称"本激励计划"）的顺利推进及有序 实施，现根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理 办法》《上海证券交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股 权激励信息披露》等有关法律、行政法规、规范性文件和《公司章程》的有关规定，并结合 公司实际情况，特制定本办法。 第一条 考核目的 第二条 ...

证券代码：688293 证券简称：奥浦迈 上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划 （修订稿） 上海奥浦迈生物科技股份有限公司 二零二四年八月 1 声 明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励计划 所获得的全部利益返还公司。 2 特别提示 一、《上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划（草 案）》（以下简称"本激励计划"）系上海奥浦迈生物科技股份有限公司（以下简 称"奥浦迈"、"公司"或"本公司"）依据《中华人民共和国公司法》《中华人民 共和国证券法》《上海证券交易所科创板股票上市规则》《上市公司股权激励管理 办法》《科创板科创板上市公司自律监管指南第四号——股权激励信息披露》等 其他有关法律、法规、规范性文件，以及《上海奥浦迈生物科技股份有限公司章 程》制订。 二 ...

FANGDA PARTNERS http://www.fangdalaw.com 2023 年限制性股票激励计划调整授予价格、作废部分已授予尚未归 属的限制性股票及修订激励计划相关事项的 法律意见书 致：上海奥浦迈生物科技股份有限公司 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国法律执业 资格的律师事务所。根据上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈" 或"公司"）与本所签订的法律顾问协议，本所担任奥浦迈 2023 年限制性股票激 励计划项目（以下简称"本激励计划"）的专项法律顾问，就本激励计划调整授予 价格（ ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.20 per 10 shares, totaling approximately RMB 25.02 million, which represents 103.64% of the net profit attributable to shareholders for the first half of 2024[5]. - The company has authorized the board to determine the specific mid-term profit distribution plan based on profit distribution conditions[5]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the mid-term distribution[5]. - The company has authorized the board to formulate a specific mid-term profit distribution plan based on the actual operating conditions and financial status for the first half of 2024[96]. Financial Performance - Shanghai Aopumai Biotechnology Co., Ltd. reported a significant increase in revenue for the first half of 2024, reaching RMB 500 million, representing a 25% year-over-year growth[12]. - The company's revenue for the first half of 2024 reached ¥143,608,281.60, representing an increase of 18.44% compared to ¥121,248,051.98 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥24,138,140.17, a decrease of 36.29% from ¥37,885,821.00 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,736,277.99, down 43.50% from ¥29,620,783.98 year-on-year[20]. - The company reported a gross margin of 60% for the first half of 2024, an improvement from 55% in the same period last year[12]. - The company reported a total profit for the first half of 2024 of RMB 30,052,311.88, a decrease of 30.0% from RMB 42,911,009.78 in the previous year[191]. Research and Development - The company plans to invest RMB 100 million in R&D for innovative drug development in the upcoming fiscal year[12]. - The company continues to invest in research and development of new technologies and products, particularly in the field of cell and gene therapy[16]. - Research and development expenses accounted for 10.71% of operating revenue, down 6.36 percentage points from the previous year[21]. - The company has developed multiple new cell culture media products, including 15 customized CHO cell culture media, with over half already used in pilot projects[38]. - The company has established a professional R&D team of over 100 members, ensuring continuous innovation and capability to address complex challenges in the biotechnology field[52]. Market Expansion and Strategy - Aopumai has set a revenue guidance for the second half of 2024, projecting an increase of 20% to reach RMB 600 million[12]. - Aopumai is investing in market expansion, targeting a 15% increase in market share within the next year[12]. - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[16]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors[7]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, advising investors to be aware of these risks[3]. - The company faces risks related to the stability of raw material supply, particularly amino acids, which are critical for cell culture media production[66]. - The company acknowledges the risk of rapid revenue growth being unsustainable due to potential customer attrition or industry fluctuations[69]. - The company is exposed to risks related to core technology leakage and intellectual property protection in the technology-intensive cell culture industry[62]. Shareholder Commitments and Governance - The company has established a mechanism to automatically extend the lock-up period by six months if the stock price falls below the IPO price for 20 consecutive trading days[107]. - The company has committed to not transferring or managing its shares for 36 months post-IPO, ensuring stability in shareholding[108]. - The company will disclose any share reduction plans 15 trading days in advance if conducted through public trading[111]. - The company emphasizes strict adherence to its commitments, with penalties for non-compliance including the forfeiture of any gains from share reductions[119]. Corporate Social Responsibility - The company has been actively involved in public welfare projects, donating RMB 40,000 annually since 2021 to support rural revitalization efforts in Yunnan and Xinjiang[103]. - The company has invested RMB 1.7264 million in environmental protection measures during the reporting period[101]. - The company is not classified as a key pollutant discharge unit and complies with environmental regulations regarding waste management[101]. Operational Efficiency - The company aims to enhance customer loyalty and trust through the expansion of its CDMO services and the establishment of long-term partnerships[60]. - The company is focusing on optimizing cell culture media to improve protein expression levels, which is crucial for reducing production costs in biopharmaceuticals[29]. - The company has established large-scale production bases compliant with GMP standards, developing various cell culture media that can replace imported brands[35].

证券代码：688293 证券简称：奥浦迈 公告编号：2024-052 上海奥浦迈生物科技股份有限公司 关于公司 2024 年度"提质增效重回报"行动方案 半年度执行情况评估报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为贯彻中央经济工作会议、中央金融工作会议精神，落实以投资者为本的理 念，积极响应上海证券交易所"提质增效重回报"专项行动的倡议并践行"以投资 者为本"的发展理念，上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或 "公司"）已于2024年4月29日正式披露《2024年度"提质增效重回报"行动方案》 （以下简称"《行动方案》"）。 为进一步落实有关工作安排，切实维护全体股东利益，公司对《行动方案》 在报告期内的执行情况进行全面评估并编制本报告，具体内容如下： 公司报告期内 CDMO 业务为客户提供稳定细胞系构建、中试生产、制剂开 发和分析等服务，协助客户获得 5 个临床批件，同时有一个项目协助客户获得 NMPA 上市批准，技术平台能力持续提升，积累了良好的口碑。 2、加强资金管理，最大化实现资金效率 ...